Wegovy: The Complete UK Guide (2026)

What is Wegovy and how does it work?

Wegovy is the brand name for semaglutide, a once-weekly injectable GLP-1 receptor agonist made by Novo Nordisk. The MHRA licenses it in the UK for weight management in adults with obesity, or with overweight plus a weight-related health condition. It works by reducing appetite, slowing gastric emptying, curbing food cravings, and supporting blood sugar regulation.

Wegovy and Ozempic contain the same active ingredient. The difference is the dose and the licensed indication: Ozempic is licensed for type 2 diabetes at lower doses (up to 1mg once weekly), whereas Wegovy is licensed for weight management at higher doses (up to 7.2mg once weekly). They are not interchangeable.

In plain English, semaglutide mimics a gut hormone the body releases after eating. It works in four main ways: it reduces appetite so meals feel satisfying sooner, it slows how quickly the stomach empties, it reduces food cravings (particularly for high-calorie foods), and it supports healthy blood sugar regulation. Combined, these effects produce sustained weight loss when paired with dietary changes and physical activity.

Unlike Mounjaro (tirzepatide), which activates two gut hormone receptors (GLP-1 and GIP), Wegovy activates GLP-1 alone. This single-receptor action is part of why average weight loss at the standard 2.4mg dose is lower in trials than tirzepatide at higher doses. The new 7.2mg Wegovy dose narrows that gap considerably.

Wegovy is delivered in a single-use auto-injector pen. You press the pen against your skin and press a button; the needle is automatic and hidden throughout, so you never handle it directly. One pen delivers one weekly dose, and one box typically contains four weekly doses.

On 14 April 2026, the MHRA approved a new single-dose 7.2mg Wegovy pen for adults with obesity (BMI 30+). Before this, the 7.2mg weekly dose required three 2.4mg injections administered on the same day. The new single-dose pen delivers the full 7.2mg in one injection. UK stock of the single-dose device is expected to roll out in the weeks following approval.

What results can you expect from Wegovy?

In the STEP 1 trial, adults on semaglutide 2.4mg lost a mean of 14.9% of their body weight over 68 weeks, compared with 2.4% on placebo. In the STEP UP trial of the new 7.2mg dose, mean weight loss reached 20.7% over 72 weeks (trial product estimand), with almost a third of participants losing 25% or more of their body weight. Results vary between individuals and depend on dose, adherence, diet, and physical activity.

STEP 1 (published in the New England Journal of Medicine, February 2021) randomised 1,961 adults with obesity or overweight plus a comorbidity, without type 2 diabetes, to semaglutide 2.4mg or placebo for 68 weeks. Mean weight loss was 14.9% with semaglutide versus 2.4% with placebo. 86.4% of semaglutide participants lost at least 5% of their body weight, compared with 31.5% on placebo.

STEP UP (published in The Lancet Diabetes & Endocrinology, 2025) evaluated semaglutide 7.2mg against semaglutide 2.4mg and placebo in 1,407 adults with obesity (BMI 30+), without type 2 diabetes, for 72 weeks. Key findings:

• Mean weight loss among participants who adhered to treatment (trial product estimand): 20.7% at 7.2mg, 17.5% at 2.4mg, 2.4% on placebo.
• Mean weight loss regardless of adherence (treatment policy estimand): 18.7% at 7.2mg, 15.6% at 2.4mg, 3.9% on placebo.
• 33.2% of 7.2mg participants lost 25% or more of their body weight, versus 16.7% on 2.4mg.
• Nearly half of 7.2mg participants achieved 20% or more weight loss.

What different percentages mean in kilograms:

Timeline: what to expect and when. Most patients notice reduced appetite within the first 2 to 4 weeks of starting treatment. Visible weight loss usually becomes apparent from month 2 to 3 onwards. The steepest rate of loss typically occurs during dose escalation, between months 2 and 5. Weight loss slows naturally as the body adjusts, and continued dietary and activity support improves long-term results.

If you stop taking Wegovy. In the STEP 4 trial, patients who switched from semaglutide to placebo at week 20 regained a significant proportion of lost weight over the following 48 weeks, while those who continued semaglutide lost further weight. This is a biological response to removing the medicine, not a personal failure. Obesity is a chronic condition, and most patients continue treatment long-term to maintain their results. If you plan to stop, your prescriber can support a structured approach.

Wegovy doses: the full titration schedule

Wegovy is started at a very low dose and gradually escalated over 16 weeks, with the aim of reaching the 2.4mg maintenance dose from week 17. Some patients achieve their goals at lower doses and do not escalate further. Others may move on to the 7.2mg dose from month 6 onwards if clinically indicated. Each dose step lasts a minimum of 4 weeks to allow the body to adjust.

The four-week rule and why it exists. Each escalation step must be at least four weeks before moving to the next. This is not arbitrary. GI side effects are most common during the first few weeks of a new dose, and tolerability improves with time at each step. Trying to escalate faster typically increases side effects without accelerating weight loss.

Staying on lower doses. Not every patient needs to reach 2.4mg. Many achieve excellent, sustained weight loss at 1mg or 1.7mg, and there is no clinical requirement to escalate further if a lower dose is working and well tolerated. Your prescriber will review your progress at each check-in and discuss whether to hold or escalate.

The 7.2mg dose. The MHRA approved 7.2mg as a maximum weekly dose in January 2026, and the new single-dose pen on 14 April 2026. The 7.2mg dose is intended for adults with obesity (BMI 30+) who have plateaued on 2.4mg or who need additional weight reduction before other options are considered. It is not a standard escalation step for all patients. The new single-dose device delivers the full 7.2mg maintenance dose in one injection, replacing the previous method of three 2.4mg injections given on the same day. The 7.2mg dose is not currently approved for overweight patients (BMI 27 to 29.9) or for patients using Wegovy for cardiovascular risk reduction.

Dose pausing. If side effects are significant at any step, staying at the current dose for an additional 4 to 8 weeks before escalating is normal clinical practice and does not mean treatment has failed. Most GI side effects settle with time, and a slower escalation often produces better long-term results than pushing through severe symptoms.

Wegovy side effects: what to expect and how to manage them

Most Wegovy side effects are mild to moderate, occur during dose escalation, and improve with time. The most common are gastrointestinal (nausea, diarrhoea, constipation, occasional vomiting), which typically settle within the first 4 to 8 weeks at each new dose. Rare but serious side effects include acute pancreatitis, which requires urgent medical attention.

Common side effects (affecting more than 1 in 10 people):

• Nausea. The most common side effect, particularly during the first 4 to 8 weeks of treatment and each escalation. Eat smaller, slower meals. Avoid fatty, greasy, and heavily spiced foods. Bland foods (toast, rice, plain chicken) are usually better tolerated. Ginger tea or plain water can help.
• Diarrhoea. Stay well hydrated. Avoid high-fat foods. Contact your prescriber if it persists for more than a few days.
• Constipation. Increase water intake and dietary fibre (vegetables, whole grains, pulses). Gentle daily exercise helps.
• Vomiting. Occasional mild vomiting can occur with escalation. Persistent vomiting beyond 24 hours should be reported to your prescriber.
• Abdominal pain. Mild discomfort during the first weeks is common. Persistent or severe pain, especially if radiating to the back, must be reported immediately (see pancreatitis below).
• Decreased appetite. Expected; this is the therapeutic effect. Occasionally, appetite suppression at higher doses becomes excessive. If you are struggling to eat enough, speak to your prescriber.
• Headache. More commonly reported with Wegovy than with some other GLP-1 treatments; usually resolves within the first few weeks.

Less common but important:

• Acute pancreatitis. Uncommon but serious. Symptoms include severe, persistent pain in the upper abdomen, often radiating to the back, with nausea and vomiting. Seek urgent medical attention.
• Gallstones. Upper right abdominal pain after fatty food. Your prescriber will assess whether further investigation is needed.
• Diabetic retinopathy worsening. Relevant only for patients with existing diabetic eye disease. Regular eye review is recommended.
• Injection site reactions. Less common than with pen devices that require manual needle attachment, because the Wegovy auto-injector minimises handling.
• Skin symptoms at 7.2mg. In STEP UP, dysaesthesia (altered skin sensation) and allodynia (sensitivity to normal touch) were reported more commonly at 7.2mg (22.9%) than at 2.4mg (6.0%). Report these to your prescriber if they occur.

Reassurance on timing. Most patients who experience nausea or other GI symptoms in the first month report that these have resolved or significantly reduced by month 2 to 3. The escalation schedule exists to give the body time to adjust. Working with your prescriber, rather than stopping treatment abruptly, is usually the better option.

Who is eligible for Wegovy in the UK?

Wegovy can be prescribed to adults with a BMI of 30 or above (obesity), or a BMI of 27 to 29.9 with at least one weight-related health condition. NHS access is limited to specialist weight management services with long waits in most areas. Private prescription is available for eligible patients within days.

Private prescription eligibility. Wegovy can be prescribed privately to adults who meet licensing criteria:

• BMI 30 or above, or
• BMI 27 to 29.9 with at least one qualifying comorbidity (such as type 2 diabetes, hypertension, dyslipidaemia, cardiovascular disease, or obstructive sleep apnoea).

BMI thresholds are reduced by 2.5 points for people of South Asian, Chinese, Middle Eastern, Black African, or African-Caribbean backgrounds, per NICE guidance. Standard contraindications include pregnancy, breastfeeding, a personal or family history of medullary thyroid cancer or MEN2 syndrome, and a history of acute pancreatitis. The new single-dose 7.2mg pen is approved only for adults with a BMI of 30 or above; patients with a BMI of 27 to 29.9 using Wegovy for weight management are not currently eligible for the 7.2mg dose.

NHS eligibility. Wegovy is available on the NHS through specialist weight management services (Tier 3 and Tier 4), subject to local commissioning. Unlike Mounjaro, there is no national phased GP rollout for Wegovy in 2026, so access depends on local specialist service capacity and waiting lists. Waits of 6 to 12 months are common in many areas, and some regions have limited or paused referrals. In practice, most patients who qualify for a private prescription will not be able to access NHS Wegovy within a clinically meaningful timeframe in 2026.

How to get Wegovy in the UK

There are two routes to Wegovy in the UK: the NHS via specialist services (long waits), and a regulated private prescription (days). Both routes require a clinical assessment before treatment, and Wegovy obtained without a prescription or without assessment is not safe.

NHS route:

1. Speak to your GP about a referral to a specialist weight management service.
2. If accepted, you are assessed by the service and Wegovy may be prescribed as part of a structured programme.
3. Waiting times are commonly 6 to 12 months.

Private route:

1. Complete an online eligibility check (typically 5 to 10 minutes).
2. An independent regulated prescriber reviews your information and health history.
3. If clinically appropriate, a prescription is issued.
4. Medication is dispensed by a GPhC-registered pharmacy and typically delivered within 2 to 3 working days.

Regulatory note. Any provider prescribing Wegovy in the UK must use a prescriber regulated by the GMC, GPhC, or NMC, and medicines must be dispensed by a GPhC-registered pharmacy. You can verify a pharmacy's registration on the General Pharmaceutical Council register and a doctor's registration on the General Medical Council register.

Wegovy cost in the UK

Private Wegovy typically starts from around £79 to £119 per month for the 0.25mg starter dose, rising to roughly £135 to £299 per month at the 2.4mg maintenance dose, and £239 to £389 per month at the 7.2mg dose. Exact prices depend on the provider and what is included. NHS access is available via specialist services at standard prescription charges, but with waits of 6 to 12 months in most areas.

Following Eli Lilly's UK price rise in September 2025, Wegovy is typically £50 to £100 per month cheaper than Mounjaro at comparable dose stages. For cost-conscious patients, this difference can be clinically relevant over a long course of treatment.

When comparing providers, always look at total cost rather than the headline price. Some providers charge separately for clinical assessment, prescribing fees, needles, sharps bin, and delivery, which can add £30 to £50 or more to the monthly bill. At Foundry, the per-order price covers clinical assessment, prescribing, needles, and a sharps bin; shipping is charged separately at checkout.

For a full breakdown of all doses, the hidden-extras problem, and a comparison of NHS, pay-as-you-go, and annual membership pricing, see our UK medical weight loss cost guide.

Wegovy vs Mounjaro: which is right for you?

Both Wegovy (semaglutide) and Mounjaro (tirzepatide) are MHRA-licensed for weight management in the UK. Mechanistically, Wegovy acts on the GLP-1 receptor alone; Mounjaro acts on both GLP-1 and GIP. The right medicine for any individual depends on clinical suitability, tolerability, cost, and prescriber assessment.

Trial data, presented independently. In SURMOUNT-1 (2,539 adults, 72 weeks, BMI 30+ or 27+ with a comorbidity, no diabetes), mean weight loss with tirzepatide reached 16.0% at 5mg, 21.4% at 10mg, and 22.5% at 15mg. In STEP 1 (1,961 adults, 68 weeks, similar population), mean weight loss with semaglutide 2.4mg was 14.9%. In STEP UP (1,407 adults, 72 weeks, BMI 30+, no diabetes), mean weight loss with semaglutide 7.2mg reached 20.7% (trial product estimand). These trials had different populations, durations, and designs; they are not head-to-head studies, and individual responses vary considerably.

Practical differences. Wegovy is delivered in a single-use auto-injector pen with no needle handling, which can be helpful for patients with needle anxiety. Mounjaro requires a needle to be attached by the patient before each injection. On cost, Wegovy is typically £50 to £100 per month cheaper than Mounjaro at comparable dose stages following Lilly's September 2025 price rise. On tolerability, both have similar GI side-effect profiles, though some patients tolerate one better than the other. Switching between them under clinical supervision is a valid option if the first does not suit.

For a full side-by-side clinical overview, see our Wegovy and Mounjaro guide.

Frequently asked questions